Sativex ® spray approved cannabis extract Posted on 23 Mar 10:50
Sativex ® spray approved cannabis extract against spasticity in multiple sclerosis in Switzerland
Wednesday, January 29th, 2014
The Sativex spray with cannabis extract for use in the oral cavity is already in several European countries in trade (for example, in Germany and the UK). In Switzerland and in France the drug recently got regulatory approval, but is not currently in distribution.
Included in the Sativex spray is a thick extract of cannabis flowers and cannabis leaves.
This extract is composed of equal parts of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD). The two active ingredients affect the endocannabinoid system, which is involved in the regulation of neuronal and neuromuscular signal transmission.
In multiple sclerosis patients, this system is severely compromised, as it comes as a result of neurodegeneration in a reduction of endogenous cannabinoids.
In the Sativex spray the psychoactive effects of THC by the antipsychotic CBD is überwiegendst prevented.
The indication of the Sativex spray is very limited: Sativex is used for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis, when the symptoms can not be adequately relieved by other anti-spastic drug therapy. In addition, an initial therapeutic trial must have produced clinically significant improvement in spasticity associated with the symptoms.
It is a titration of up to two weeks is required to achieve the optimum dose.
The patient may gradually by a puff of spray per day increase the dose up to a maximum of 12 sprays daily until optimal relief of symptoms occurs. Distances of at least 15 minutes should elapse between the bursts. The Sativex spray is administered under the tongue or on the inside of the cheek